L'Oréal and Walgreens Back $27.5M Round for Chinese Biomaterials Firm

L'Oréal and Walgreens have co-led a US$27.5 million Series A and A+ financing round for Shenzhen Boyin Biotechnology, a Chinese start-up building AI-driven biomaterials for cosmetics, healthcare and nutrition. The round, disclosed without a per-investor breakdown, signals how major beauty and pharmacy groups now treat ingredient-level biotechnology as a strategic asset rather than a procurement afterthought.

Who is investing, and through which vehicles?

The financing was co-led by three parties:

• BOLD, L'Oréal's corporate venture fund;
• a joint Walgreens–Guangzhou Pharmaceutical investment fund;
• Guangxin Fund, a Chinese investor.

L'Oréal's participation extends an existing relationship rather than opening one. Shenzhen Boyin's biomaterials platform, PAM2L, took part in L'Oréal's 2024 BIG BANG beauty-technology programme, and the two companies already run a research partnership focused on translating biotechnology innovations into commercial applications. The new capital is intended to deepen that translation, funding research and development, production capacity expansion and international commercialisation.

What does the company actually make?

Founded in 2021, Shenzhen Boyin combines synthetic biology (the engineering of biological systems to manufacture target molecules) with artificial intelligence to design advanced biomaterials. Its named outputs are two: recombinant mussel adhesive protein and Colamin. Neither the source nor the announcement specifies the formulation concentrations, clinical evidence class or regulatory status of these materials in cosmetic applications — a gap worth noting given that adhesive proteins and bioactive amines are marketed on function claims that rarely come with published trial data.

That absence matters. For dermatology readers accustomed to judging actives by concentration and evidence class, the deal currently offers corporate validation without disclosed performance data. What the funding does establish is capacity: the round is directed at manufacturing scale-up and international commercialisation, meaning these ingredients could reach formulation pipelines outside China within a few product cycles.

Why are global manufacturers chasing biotech ingredients?

The investment reflects growing interest among global cosmetics manufacturers in AI-driven biotechnology and next-generation biomaterials as sources of formulation innovation and competitive differentiation. The logic is straightforward. Proprietary biomaterials created in-house or through venture stakes are harder to replicate than commodity actives, and they give marketing teams a defensible ingredient story.

For L'Oréal specifically, the partnership strengthens access to China's biotechnology ecosystem while supporting the development of new ingredients and manufacturing technologies that could be scaled across international cosmetics markets. The comparison with the BIG BANG programme is instructive: L'Oréal is increasingly using its accelerator and its venture fund as a two-stage funnel, first screening start-ups through an innovation programme, then deploying capital into those that survive it.

Walgreens' presence adds a second dimension. Through the Walgreens–Guangzhou Pharmaceutical fund, a US retail-pharmacy group gains exposure to healthcare and nutrition biomaterials, not merely beauty ones — consistent with the round's stated three-domain scope.

What is still unknown?

Several material details remain undisclosed. The announcement does not specify the individual cheque sizes, the post-money valuation, or a timeline for commercial launches. It does not say which of the two named biomaterials is closest to market, nor whether either has cleared regulatory review in the European Union or the United States. For now, the story rests on capital committed and partnerships formalised, not on published efficacy endpoints.

The forward signal is nonetheless clear: as L'Oréal deepens its China biotech exposure and Walgreens bridges into bio-derived health ingredients, expect recombinant biomaterials engineered by AI platforms such as PAM2L to appear in ingredient lists and supplier announcements before they appear in peer-reviewed dermatology literature.